Related Articles
20 December 2022
27 July 2021
iOnctura Project Evaluating Novel PI3Kδ-inhibitor IOA-244 in Lymphoma to be Co-funded by Innosuisse
20 July 2021
iOnctura Announces First Subject Dosed in Healthy Volunteer Study of Next Generation Autotaxin Inhibitor IOA-289
14 July 2020
3B Future Health Fund, previously
known as Helsinn Investment Fund S.A., SICAR, today announces that it has invested in iOnctura SA, a clinical stage biopharmaceutical company developing a pipeline of next generation molecules targeting cancer and fibrosis.
Get in touch
Thank you for your form submission, we will get in contact with you shortly.
